CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Total operating revenue	$ 64,977	$ 52,275	$ 181,059	$ 150,699
Operating expenses
Selling, general and administrative expense	31,963	12,730	90,117	35,120
Depreciation and amortization	1,134	850	3,219	2,421
Total operating expenses	85,074	54,432	237,931	155,725
Loss from operations	(20,097)	(2,157)	(56,872)	(5,026)
Other non-operating expense (income)
Interest expense, net	1,497	78	1,632	260
Change in fair value of derivative warrant liabilities	159	0	(445)	0
Change in fair value of earnout liabilities	(3,581)	0	(53,821)	0
Change in fair value of conversion option derivative liabilities	(15,510)	0	(15,510)	0
Gain on debt extinguishment	0	0	(183)	(5,186)
Other, net	36	(54)	172	(1,126)
Total other non-operating (income) loss	(17,399)	24	(68,155)	(6,052)
Income (loss) before provision for income (loss) taxes	(2,698)	(2,181)	11,283	1,026
Income tax benefit (expense)	24	(799)	(124)	(1,797)
Net income (loss)	$ (2,674)	$ (2,980)	$ 11,159	$ (771)
Net income (loss) per share attributable to common stockholders:
Basic (in usd per share)	$ (0.03)	$ (0.05)	$ 0.12	$ (0.01)
Diluted (in usd per share)	$ (0.17)	$ (0.05)	$ (0.03)	$ (0.01)
Weighted-average number of shares outstanding:
Basic (in shares)	72,184,366	66,021,828	72,807,277	64,977,298
Diluted (in shares)	79,581,304	66,021,828	75,300,018	64,977,298
Patient services
Revenue
Total operating revenue	$ 44,627	$ 32,967	$ 118,793	$ 92,375
Operating expenses
Direct costs	36,126	25,391	96,379	72,051
Dispensary
Revenue
Total operating revenue	18,839	17,918	57,736	53,318
Operating expenses
Direct costs	15,738	15,279	47,816	45,639
Clinical trials & other
Revenue
Total operating revenue	1,511	1,390	4,530	5,006
Operating expenses
Direct costs	$ 113	$ 182	$ 400	$ 494